About
Anida Pharma develops first-in-class therapeutics that activate endogenous protective mechanisms to prevent and slow progressive eye diseases using a topical neuroprotectant molecule, AP-001, derived from neuroprotectin D1.
Explore Anida Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.